Sylvie Pariel

Sylvie Pariel

Auto-generated profile, based on publicly available information

Sylvie Pariel

Hôpital Charles Foix, 7 avenue de la République, 94200 Ivry sur Seine, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
Joel BelminJoel Belmin
Joel Belmin
LKLyamna Khellaf
Lyamna Khellaf
SPSylvie Pariel
Sylvie Pariel
WJWitold Jarzebowski
Witold Jarzebowski
LVLucie Valembois
Lucie Valembois
CLCarmelo Lafuente-Lafuente
Carmelo Lafuente-Lafuente
Background: Identifying and assessing degree and type of frailty among older persons is a major challenge when targeting high risk populations to identify preventive interventions. The Vulnerable Elders Survey-(VES-13) is a simple instrument to identify frailty defined as risk for death, functional decline or institutionalization. Objective: Translate VES-13 into French and validate it. Methods: The French version of VES-13 was developed by forward-backward translation of the VES-13 survey instrument. The authors assessed its feasibility, construct validity, and ability to predict the combined outcomes of admission to institution or death at 18 months, in 135 persons over 70 years of age living in the community. Subjects were recruited from three settings: Group 1 – a health prevention center (n = 45); Group 2 – an ambulatory care geriatric clinic (n = 40); and Group 3 – an intermediate care hospital unit (n = 50). The combined outcomes data were recorded by telephone interview with participants or a proxy. Results: Feasibility of the French version, named Echelle de Vulnérabilité des Ainés-13 or EVA-13, was excellent. The scale classified 5 (11%) persons as vulnerable (score of 3 or more) in Group 1, 23 (58%) in Group 2 and 45 (90%) in Group 3 (p < 0.001) with scores of 0.91 +/− 1.16, 4.27 +/− 3.17 and 6.90 +/− 3.17, respectively (p < 0.001). At follow-up, among the 60 non-vulnerable subjects, 58 (96%) were alive and living at home, whereas 46 (65%) of the 70 vulnerable subjects were alive and living at home (p < 0.001). Conclusions: EVA-13 was determined to be valid and reliable.

2 August 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
VZVictoria Zolnowski-Kolp
Victoria Zolnowski-Kolp
NDNathavy UM DIN
Nathavy UM DIN
CHCharlotte Havreng-Théry
Charlotte Havreng-Théry
SPSylvie Pariel
Sylvie Pariel
JVJacques-Henri Veyron
Jacques-Henri Veyron
Joel BelminJoel Belmin
Joel Belmin
Background: Frailty assessment is a major issue in geriatric medicine. The Vulnerable Elders Survey-13 (VES-13) is a simple and practical tool that identifies frailty through a 13-item questionnaire completed by older adults or their family caregivers by self-administration (pencil and paper) or by telephone interview. The VES-13 provides a 10-point score that is also a recognized mortality predictor. Objective: This study aims to design an electronic version of the Echelle de Vulnérabilité des Ainés-13, the French version of the VES-13 (eEVA-13) for use on a digital tablet and validate it. Methods: The scale was implemented as a web App in 3 different screens and used on an Android tablet (14.0× 25.6 cm). Participants were patients attending the outpatient clinic of a French geriatric hospital or hospitalized in a rehabilitation ward and family caregivers of geriatric patients. They completed the scale twice, once by a reference method (self-administered questionnaire or telephone interview) and once by eEVA-13 using the digital tablet. Agreement for diagnosis of frailty was assessed with the κ coefficient, and scores were compared by Bland and Altman plots and interclass correlation coefficients. User experience was assessed by a self-administered questionnaire. Results: In total, 86 participants, including 40 patients and 46 family caregivers, participated in the study. All family caregivers had previously used digital devices, while 13 (32.5%) and 10 (25%) patients had no or infrequent use of them previously. We observed no failure to complete the eEVA-13, and 70% of patients (28/40) and no family caregivers needed support to complete the eEVA-13. The agreement between the eEVA-13 and the reference method for the diagnosis of frailty was excellent (κ=0.92) with agreement in 83 cases and disagreement in 3 cases. The mean difference between the scores provided by the 2 scales was 0.081 (95% CI–1.263 to 1.426). Bland and Altman plots showed a high level of agreement between the eEVA-13 and the reference methods and interclass correlation coefficient value was 0.997 (95% CI 0.994-0.998) for the paper and tablet group and 0.977 (95% CI 0.957-0.988) for the phone and tablet groups. The tablet assessment was found to be easy to use by 77.5% (31/40) of patients and by 96% (44/46) of caregivers. Finally, 85% (39/46) of family caregivers and 50% (20/40) of patients preferred the eEVA-13 to the original version. Conclusions: The eEVA-13 is an appropriate digital tool for diagnosing frailty and can be used by older adults and their family caregivers. The scores obtained with eEVA-13 are highly correlated with those obtained with the original version. The use of health questionnaires on digital tablets is feasible in frail and very old patients, although some patients may need help to use them.

22 August 2024
Verified
Book Chapter
Open access
PDF file
NDNathavy UM DIN
Nathavy UM DIN
FMFlorian Maronnat
Florian Maronnat
SPSylvie Pariel
Sylvie Pariel
FBFadi Badra
Fadi Badra
Joel BelminJoel Belmin
Joel Belmin
The diagnosis of neurocognitive diseases is an important health issue for patients, families and healthcare professionals. The need to develop rapid, high-performance screening tools would improve access to care. The Clock Drawing Test (CDT) is widely used and validated with the older adults, and its digital version is becoming increasingly widespread. We propose to confirm its validity in a population of old patients hospitalized in a geriatric unit, and secondly to verify its performance in comparison with the reference diagnosis made by a specialized team in a memory consultation. CDTs were collected from older hospitalized patients, both in paper form and digitally on a touchscreen tablet. The results show good agreement between the paper and digital versions (kappa coefficient = 0.81). Sensitivity and specificity of the digital CDT were 0.84 and 0.59 respectively for the diagnosis of major cognitive disorders. The corresponding values were 0.72 and 0.59 for the diagnosis of mild neurocognitive disorders. User questionnaires indicate that older participants find the digital tablet easy to use. However, they prefer to use paper, even if they are open to learning how to use the tablet.

1 February 2019 in La Presse Médicale
Verified
Journal Article
Closed access
ABAmaury Broussier
Amaury Broussier
LVLucie Valembois
Lucie Valembois
CLCarmelo Lafuente-Lafuente
Carmelo Lafuente-Lafuente
JDJean-Philippe David
Jean-Philippe David
SPSylvie Pariel
Sylvie Pariel

18 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
NDNathavy UM DIN
Nathavy UM DIN
FMFlorian Maronnat
Florian Maronnat
BOBruno Oquendo
Bruno Oquendo
SPSylvie Pariel
Sylvie Pariel
CLCarmelo Lafuente-Lafuente
Carmelo Lafuente-Lafuente
Joel BelminJoel Belmin
Joel Belmin
Background/Objectives: Mild neurocognitive disorder (mNCD) is a state of vulnerability, in which individuals exhibit cognitive deficits identified by cognitive testing, which do not interfere with their ability to independently perform in daily activities. New touchscreen tools had to be designed for cognitive assessment and had to be at an advanced stage of development but their clinical relevance is still unclear. We aimed to identify digital tools used in the diagnosis of mNCD and assess the diagnostic performance of these tools. Methods: In a systematic review, we searched 4 databases for articles (PubMed, Embase, Web of science, IEEE Xplore). From 6516 studies retrieved, we included 50 articles in the review in which a touchscreen tool was used to assess cognitive function in older adults. Study quality was assessed using the QUADAS-II scale. Data from 34 articles were appropriate for meta-analysis and were analyzed using the bivariate random-effects method (STATA software version 19). Results: The 50 articles in the review totaled 5974 participants and the 34 in the meta-analysis, 4500 participants. Pooled sensitivity and specificity were 0.81 (95%CI: 0.78 to 0.84) and 0.83 (95%CI: 0.79 to 0.86), respectively. High heterogeneity among the studies led us to examine test performance across key characteristics in a subgroup analysis. Tests that are short and self-administered on a touchscreen tablet perform as well as longer tests administered by an assessor or on a fixed device. Conclusions: Cognitive testing with a touchscreen tablet is appropriate for screening for mNCD. Further studies are needed to determine their clinical utility in screening for mNCD in primary care settings and referral to specialized care. This research received no external funding and is registered with PROSPERO under the number CRD42022358725.

15 November 2026 in JMIR Preprints
Verified
Preprint
Open access
NDNathavy UM DIN
Nathavy UM DIN
FMFlorian Maronnat
Florian Maronnat
SPSylvie Pariel
Sylvie Pariel
QBQuentin Le Boterff
Quentin Le Boterff
MTMaxime Teremetz
Maxime Teremetz
Joel BelminJoel Belmin
Joel Belmin
BACKGROUND The prevalence of neurocognitive disorders (NCD) is increasing as the population ages. The diagnosis includes a time-consuming medical and neuropsychological battery of tests in specialized centers. The development of effective screening tools could benefit primary care professionals by improving referral practices. OBJECTIVE To explore the feasibility of a digital tablet-based investigation comprising a wide set of questions combined with cognitive and manual dexterity tasks, study their relevance for the diagnosis of NCD, and select the best combination of variables likely to help the screening. METHODS We conducted a prospective diagnosis study conducted in 2 memory clinics. We recruited older adults who underwent a comprehensive cognitive assessment with a specialized team leading to a reference diagnostic. This consisted in 3-category classification: no NCD, mild NCD (m-NCD) and major NCD (M-NCD). At the same time, they completed a variety of testings implemented on a touchscreen tablet which included a medical questionnaire, cognitive and manual dexterity tasks. We analyzed the dataset using several approaches to determine the most important variables for identifying M-NCD, or any NCD (either m-NCD or M-NCD). RESULTS We included 160 participants whose reference diagnosis were M-NCD for 58 of them, m-NCD for 52, and no NCD for 50. The feasibility of the index test battery was excellent; all participants answered the medical questionnaire, all completed the cognitive tasks, and there were 7 protocol stops during the manual dexterity tasks due to pain and poor hand detection. We achieved a final model with 9 variables for the detection of M-NCD and 5 for any NCD. The variables relevant for identifying M-NCD are those related to loss of independence, frailty, information processing, sleep, and executive functions related to manual dexterity (inhibition and mental flexibility). Sensitivity was 81% and specificity 86%, with an AUC of 0.90 for the screening of M-NCD. The variables relevant to identifying NCD are memory, categorization, processing speed, the presence of hypertension, and success in a motor task requiring mental flexibility. Sensitivity was 81% and specificity 82% with and AUC of 0.91 for the detection of any NCD. CONCLUSIONS We identified 2 combinations of variables that can distinguish any NCD from M-NCD with satisfactory performance for a screening. CLINICALTRIAL This study has been registered in clinical trial under the number NCT06032611. The protocol has been approved by the French national ethic committee (Comité de Protection des Personnes Est III) under the number IDRCB2022-A00609-34.